BioNTech

BioNTech
source
Name	BioNTech SE
Foundation	0 2008
Founders	Uğur Şahin, Özlem Türeci, Christoph Huber
Location	Mainz, Germany
Key people	Uğur Şahin (CEO), Özlem Türeci (CMO)
Industry	Biotechnology, Pharmaceutical industry
Products	BNT162b2
Num employees	~2,000 (2021)

BioNTech. BioNTech SE is a German biotechnology company headquartered in Mainz that is focused on developing and manufacturing active immunotherapies for a range of diseases, most notably cancer. Founded in 2008 by physician-scientists Uğur Şahin and Özlem Türeci alongside oncologist Christoph Huber, the company pioneered the use of messenger RNA (mRNA) technology for therapeutic purposes. Its global prominence was cemented through a pivotal collaboration with American pharmaceutical giant Pfizer to rapidly produce one of the first effective vaccines against the COVID-19 pandemic.

History

The company was established in 2008 by its chief executive officer, Uğur Şahin, its chief medical officer, Özlem Türeci, and Christoph Huber, a former professor at the Johannes Gutenberg University Mainz. Initial research operations were based in Mainz, with early financing secured from strategic investors like the Struengmann Family Office, which had previously backed the successful generics firm Hexal AG. For its first decade, BioNTech operated primarily as a research-stage oncology firm, advancing its core mRNA platform and attracting partnerships with major entities such as Genentech and the Bill & Melinda Gates Foundation. A significant milestone was its initial public offering on the NASDAQ in October 2019, which provided substantial capital to accelerate its clinical programs just prior to the global health crisis.

Technology and platforms

The company's foundational technology is based on messenger RNA, which instructs cells to produce proteins that can train the immune system to recognize and combat pathogens or cancerous cells. Beyond its core mRNA platform, BioNTech maintains a diversified portfolio of complementary immunotherapy approaches, including cell therapies utilizing CAR-T and TCR technologies, targeted cancer antibodies, and small-molecule immunomodulators. Key innovations include its proprietary Lipid nanoparticle delivery systems to protect and transport mRNA into cells, and its FixVac platform, which combines multiple shared tumor antigens to create "off-the-shelf" cancer vaccines. These platforms are supported by advanced manufacturing capabilities and artificial intelligence tools for target discovery and clinical trial design.

COVID-19 vaccine development

In January 2020, following the publication of the SARS-CoV-2 genetic sequence, the company initiated "Project Lightspeed" to develop a vaccine candidate. This effort was supercharged by a strategic partnership with Pfizer, which provided global clinical development, manufacturing, and distribution expertise. The collaboration rapidly advanced the mRNA candidate BNT162b2 through large-scale global trials, including critical Phase III studies conducted across multiple continents. In December 2020, the vaccine received the world's first full regulatory authorization for a COVID-19 prevention tool from the Medicines and Healthcare products Regulatory Agency in the United Kingdom, followed swiftly by an Emergency Use Authorization from the U.S. Food and Drug Administration. The vaccine's deployment, under the brand name Comirnaty, became a cornerstone of the public health response in numerous countries, including the United States, European Union, and Japan.

Partnerships and collaborations

BioNTech has built an extensive network of strategic alliances to complement its internal research. Its most historic partnership is with Pfizer for the co-development and commercialization of COVID-19 vaccines, which was expanded to include work on shingles and influenza. In oncology, the company has longstanding collaborations with Genentech, a member of the Roche Group, to develop individualized cancer vaccines, and with Regeneron to combine vaccines with checkpoint inhibitors. Other significant agreements include alliances with the European Commission for pandemic preparedness, with the Fosun Pharmaceutical Group for vaccine development and distribution in China, and with the UK government to establish a research and manufacturing center in Cambridge.

Corporate affairs

The company is incorporated as a European public company (SE) and is led by its founders, Uğur Şahin and Özlem Türeci. Its headquarters and primary research facilities remain in Mainz, with additional sites in Berlin and Cambridge. Following the success of its COVID-19 vaccine, BioNTech's financial position transformed dramatically, generating substantial revenue that is being reinvested into expanding its oncology pipeline, scaling global manufacturing infrastructure, and advancing new infectious disease projects. The company is a constituent of the DAX index on the Frankfurt Stock Exchange and maintains its listing on the NASDAQ. Its corporate strategy emphasizes building a broad clinical portfolio while leveraging its mRNA technology platform for future pandemic preparedness.

Category:Biotechnology companies of Germany Category:Companies listed on the Frankfurt Stock Exchange Category:Companies listed on NASDAQ